Norfolk Southern Corporation NFS.DE XETRA · Industrials · United States
301.25 € +1.26% +3.75 €
Summary
52 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 21 USD is left as net profit.
- Analysts expect revenue to grow by 10% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue fell by 1.5% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 27.2 USD for 1 USD of yearly profit. Over the last five years it was 23.3 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 4.5% a year over 5 years. Over the last 3 years it fell by 1.5% a year. For the next fiscal year analysts expect revenue to grow by 10%. Earnings per share fell by 2.8% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 67 USD
- Sales and administration -0.9 USD
- Taxes and other 13 USD
- Net profit 21 USD
Net profit, industry median (Railroads) 8.4 USD
Out of every 100 USD of revenue, 21 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 9.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 1.58%
- Paid out of profit
- 43%
You receive 4.67 € per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 20
- Hold 20
- Sell 3
No analyst has published a price target.
47% of the analysts recommend buying.
Analysts in detail